What Biopharmaceutical and Medical Device Companies Need to Know About Telemedicine and Patient Care

The third webinar in our series on "Addressing Challenges and Mitigating Risks During the COVID-19 Pandemic and Beyond" addresses:

• Basic regulatory framework governing telehealth
  • State
  • Licensure laws
  • Telehealth laws
  • Corporate practice of medicine
  • Coverage and reimbursement
• Federal
  • Coverage and reimbursement
• Categories of regulatory waivers instituted for public health emergency
• Privacy and cybersecurity considerations
  • Pre-COVID-19
  • In response to COVID-19
• Hypothetical—A pharmaceutical company partners with a telehealth company (with and without a contracted pharmacy)

About the Webinar Series

Life sciences companies are doing their best to conduct business through remote customer interactions, and many expect that the expanded use of such technologies will persist well beyond the current crisis. While the life sciences industry can address many healthcare practitioner (HCP) and patient needs in this manner, the general rules, guidances and codes governing such interactions were not necessarily written with remote interactions in mind. Thus, enforcement risks may emerge in the absence of careful planning and strong safeguards.

Our webinar series delves into these issues to (1) identify the potential legal, regulatory and compliance risks, and (2) provide practical considerations for planning and successful implementation.

* * * * *

To help our clients navigate the coronavirus (COVID-19) crisis, Arnold & Porter has established a Coronavirus Task Force covering a wide range of issues and challenges. Subscribe to our "Coronavirus (COVID-19)" mailing list to receive our latest client Advisories and register for upcoming webinars.